Literature DB >> 24392907

Current concepts in managing central serous chorioretinopathy.

Howard F Fine, Michael D Ober, Seenu M Hariprasad.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24392907     DOI： 10.3928/23258160-20131220-01

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN： 2325-8160            Impact factor:   1.300


× No keyword cloud information.
  4 in total

1.  Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.

Authors:  E Smretschnig; S Hagen; C Glittenberg; R Ristl; I Krebs; S Binder; S Ansari-Shahrezaei
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

2.  The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case-control study.

Authors:  Abdullah Ozkaya; Ruveyde Garip; Zeynep Alkin; Muhittin Taskapili
Journal:  Int J Retina Vitreous       Date:  2017-06-12

3.  Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Authors:  Masood Naseripour; Khalil Ghasemi Falavarjani; Ahad Sedaghat; Arezoo Karimi Moghaddam; Sadaf Nasserisina; Sayyed Amirpooya Alemzadeh
Journal:  J Ophthalmic Vis Res       Date:  2016 Jan-Mar

4.  Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy.

Authors:  Róbert Gergely; Illés Kovács; Zsuzsanna Récsán; Gábor László Sándor; Cecília Czakó; Zoltán Zsolt Nagy; Mónika Ecsedy
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.